WP-DLRWM
Five-residue intestinally absorbable anticoagulant peptide from Whitmania pigra trypsin hydrolysate — Fang 2025 peptidomics + everted-gut-sac validation.
Mechanistic Evidence Box
Preclinical / mechanistic- Page type
- Compound profile
- Evidence type
- Five-residue intestinally absorbable anticoagulant peptide from Whitmania pigra trypsin hydrolysate — Fang 2025 peptidomics + everted-gut-sac validation.
- Evidence level
- In vitro
- Drug vs leech
- Synthetic analog
- Safety domains
- Bleeding
Clinical translation limit
DLRWM's in vitro / ex vivo anticoagulant activity does NOT establish clinical efficacy. No FDA-approved derivative exists; bioavailability inference from the everted-gut-sac model does not equate to human oral pharmacokinetic validation.
Molecular Profile
- Category
- Anticoagulant
- Evidence tier
- Preclinical
- Molecular weight
- 720 Da
- Source species
- Whitmania pigra
- Discovered
- 2025 · Fang KX et al.
Biological Targets
- → coagulation cascade (Critic-G1 weighted multi-parameter anticoagulation model)
Key Citations
- Fang KX et al. (2025), Molecules · PMID 40807359
External Resources
Related Anticoagulant Compounds
Hirudin
The most potent natural thrombin inhibitor — and the molecular template for three FDA-approved direct thrombin inhibitor drugs.
Antistasin
Factor Xa inhibitor — prototype molecule that inspired the entire DOAC drug class (rivaroxaban, apixaban).
Ghilanten
Factor Xa inhibitor with anti-metastatic activity in animal cancer models — translational dual-use compound.
Lefaxin
Factor Xa inhibitor with anti-inflammatory properties.